CrunchBase is hiring! Check out our open positions →
Register | Login or Login

General Information

Websitezogenix.com
CategoryBioTech
Phone858.259.1165
Emailinfo@zogenix.com
Employees50
Founded2006
Descriptionbiotechnology company

Offices

HQ
12671 High Bluff Dr
San Diego, CA, 92130
USA

People

Co-founder, CEO
President, COO
Director
Director
Director
Director
Director
Director
Chairman

Funding

Tags

Zogenix

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.

We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Recent Milestones

Videos

Screenshots

Zogenix screenshot
Above: Zogenix Screenshot -- #1
Uploaded: 9/24/09

Sources

  1. Zogenix, Inc. Raises $60 Million In Series A Venture Financing; Names Board of Directors (zogenix.com) [edit]
  2. Zogenix Raises $18 Million in Preferred Stock Financing (zogenix.com) [edit]
  3. SEC D (sec.gov) [edit]
  4. SEC D/A (sec.gov) [edit]
  5. Zogenix Secures $35 Million Debt Facility And Raises $15 Million Investment Capital (zogenix.com) [edit]
  6. Pharma Co Zogenix Files To Sell Up To $90M Of Stock In IPO (online.wsj.com) [edit]
    Zogenix Posts Modest Loss In Public Debut (fis.dowjones.com) [edit]
Edit This Page
Last Edited 11/29/10

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

Recent Incoming Links

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy